India’s Drug Regulator Suspends Bengaluru HCG Cancer Center’s Ethics Panel Over Grave Clinical Trial Safety Violations

BENGALURU — In a major enforcement action rattling India’s clinical research sector, the nation’s apex drug regulatory body, the Central Drugs Standard Control Organisation (CDSCO), has suspended the registration of the central Ethics Committee (EC) at HCG Oncology Hospital’s KR Road unit in Bengaluru for 24 months. The stringent 2-year suspension follows an investigation that uncovered grave irregularities in reporting serious adverse events (SAEs), patient casualties, and systemic conflicts of interest during clinical trials.

The official order, dated June 12, 2026, and signed by Drug Controller General of India (DCGI) Dr. Rajeev Singh Raghuvanshi, effectively bars the flagship cancer-care facility from approving or overseeing any new clinical trials or bioavailability/bioequivalence (BA/BE) studies. While ongoing trials will be permitted to continue under strict, direct monitoring by regulatory authorities, the action marks one of the most significant regulatory penalties imposed on a major corporate healthcare chain in India in recent years.

The Regulatory Audit: Key Findings of Safety Failures

The CDSCO’s punitive action stems from two risk-based inspections conducted by central investigators at the HCG-Bangalore Institute of Oncology. The audits exposed multiple critical deficiencies in how the institutional ethics committee—which is legally mandated to act as an independent watchdog for patient safety—was operating.

According to regulatory documents, the committee systematically failed to adhere to the statutory timelines for reporting severe patient outcomes. Investigators documented the following key violations:

• Failure to Report Fatalities and Injuries: The Ethics Committee failed to report at least three cases of clinical trial-related injuries and three patient deaths within the legally prescribed timelines.

• Withholding Crucial Data: The panel did not provide necessary specific details regarding an additional four cases of patient injuries and four deaths that occurred during active clinical testing.

• Lack of Administrative Transparency: The facility failed to maintain or submit signed minutes of official committee meetings, notably leaving a gap for the entire year of 2022.

• Unaddressed Conflicts of Interest: The oversight body failed to obtain mandatory “no conflict of interest” disclosures from its sitting KR Unit EC members.

• Deficient Safety Oversight: Regulators found severe deficiencies in the committee’s execution of SAE causality assessments—the process that determines whether a patient’s injury or death was directly caused by the experimental drug.

These operational failures directly violate India’s New Drugs and Clinical Trials Rules, 2019. Under these guidelines, clinical investigators must report any serious adverse event to the DCGI, the trial sponsor, and the concerned Ethics Committee within 24 hours of its occurrence. A comprehensive, analyzed report must follow within 14 calendar days.

Internal Whistleblower Raised Alarm Months Prior

The CDSCO’s enforcement action validates internal alarms raised more than a year ago. In March 2025, Justice P. Krishna Bhat (Retd.), the former chairperson of HCG’s Institutional Ethics Committee, resigned from his post in protest. In a scathing resignation letter dated March 5, 2025, Justice Bhat detailed severe compromises to patient safety and blatant violations of global ethical norms.

Justice Bhat revealed that Dr. Sathish, the Director of Clinical Trials at HCG, was simultaneously acting as the Principal Investigator (PI) or co-PI for numerous trials. This dual role created a structural conflict of interest, as he was effectively tasked with independently evaluating trials he was personally running. Furthermore, Justice Bhat alleged that the committee’s safety recommendations were routinely ignored, trial design flaws went unanswered by presenters, and strict patient inclusion criteria were relaxed to boost enrollment numbers.

Following these disclosures, the Karnataka Health Department intervened. State health officials wrote to the DCGI requesting an immediate federal probe, noting that the allegations threatened to “compromise patient safety, regulatory compliance, and institutional integrity.”

What an Ethics Committee Does—and Why It Matters

For the general public, terms like “Ethics Committee” can sound administrative, but these bodies serve as the primary line of defense for human subjects involved in medical research.

A multidisciplinary Ethics Committee is composed of medical experts, legal professionals, theologians or ethicists, and laypersons from the community. According to guidelines outlined in the Indian Journal of Medical Ethics, these panels are legally entrusted with reviewing research proposals before they begin and actively monitoring approved research to ensure patient welfare is never sacrificed for commercial or scientific advancement.

“The primary responsibility of a multidisciplinary ethics committee is protecting the safety and welfare of clinical trial subjects,” explains Dr. Savita Kumari, a clinical research ethics specialist who has served on multiple Indian Ethics Committees. “Without proper supervisory mechanisms independent of research, breaches in protocol by investigators will remain unnoticed, or serious violations will become public knowledge only after unethical practices have occurred.”

When an EC fails to report an SAE or a patient death, it leaves trial participants vulnerable. Timely reporting is vital because if an experimental drug causes unexpected harm at one site, regulators must immediately evaluate whether trials across the country need to be paused to protect other patients.

[STAGES OF MANDATORY SAE REPORTING IN INDIA]
  │
  ├──► Within 24 Hours: Investigator must report SAE to DCGI, Sponsor, and EC.
  │
  ├──► Within 14 Days: Detailed analysis report submitted for evaluation.
  │
  ├──► Within 30 Days: EC forwards report to DCGI with opinions on financial compensation.
  │
  └──► Within 60 Days: Expert Committee issues final recommendations on compensation.

HCG’s Response and Institutional Impact

Healthcare Global Enterprises Limited (HCG), one of India’s largest cancer-care networks—backed by the global private equity firm KKR (Kohlberg Kravis Roberts)—sought to assure investors and the public that the fallout would be contained.

In an official statement, the company noted:

“Based on current assessment, there is no significant impact on financial operations or other activities of the company. The suspension is addressed to and limited to the KR Unit Ethics Committee and does not extend to any other ethics committees or other operations (including hospital operation and patient care), or any other unit of the company.”

The corporate entity added that it is actively exploring legal remedies to challenge the suspension. HCG has previously strongly defended its research track record, asserting that it conducts its extensive clinical trial portfolio with the “utmost transparency and prioritizing patient safety.”

Public Health Implications and Next Steps for Patients

This regulatory crackdown represents a pivotal moment for India’s clinical trial landscape. Over the past two decades, India has emerged as a global hub for clinical research due to its diverse patient population and lower operational costs. However, historically, the sector has faced severe criticism regarding lax oversight. Regulatory experts note that stringent enforcement, such as this 24-month suspension, is vital to restoring international and domestic trust in Indian research data.

For patients and health-conscious consumers, this development underscores the necessity of self-advocacy. If you or a loved one are considering enrolling in a clinical trial, medical experts recommend asking the principal investigator the following direct questions before participating:

1. Has this clinical trial been formally approved by a registered and compliant Institutional Ethics Committee?

2. What are the established protocols for reporting tracking side effects or serious adverse events?

3. What specific medical care and financial compensation are guaranteed if I experience trial-related harm?

For the medical community, the HCG suspension serves as a stark reminder that protocol compliance and institutional transparency are non-negotiable, even under intense commercial pressures to deliver rapid research outcomes.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• “CDSCO bars HCG Hospital’s Bengaluru unit from conducting new clinical trials.” Business Standard, June 18, 2026.